**Supplementary Table 1. Comparison of the individual NOACs**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | Dabigatran(n=108) | Rivaroxaban(n=104) | Apixaban(n=114) | P-value |
| Age, years | 56.3 ± 10.8 | 59.0 ± 11.9 | 59.6 ± 11.2 | 0.076 |
| Male, n (%) | 84 (77.8) | 75 (72.1) | 84 (73.7) | 0.618 |
| Paroxysmal AF, n (%) | 68 (63.0) | 55 (52.9) | 79 (69.3) | 0.043 |
| AF duration, months | 40.8 ± 44.5 | 45.1 ± 46.2 | 55.0 ± 61.1 | 0.139 |
| BMI, kg/m2 | 25.2 ± 3.3 | 25.6 ± 3.6 | 25.3 ± 3.4 | 0.675 |
| Comorbidities |  |  |  |  |
| Heart failure, n (%) | 15 (13.9) | 15 (14.4) | 13 (11.4) | 0.778 |
|  Hypertension, n (%) | 44 (40.7) | 49 (47.1) | 47 (41.2) | 0.580 |
| Diabetes, n (%) | 11 (10.2) | 23 (22.1) | 13 (11.4) | 0.025 |
|  Stroke/TIA, n (%) | 11 (10.2) | 21 (20.2) | 8 (7.0) | 0.009 |
|  Vascular disease, n (%) | 7 (6.5) | 10 (9.6) | 8 (7.1) | 0.662 |
| CHA2DS2-VASc score | 1.4 ± 1.3 | 2.0 ± 1.5 | 1.5 ± 1.4 | 0.003 |
| Echocardiographic measures |  |  |  |  |
| LA dimension, mm | 41.1 ± 5.8 | 42.3 ± 6.2 | 40.2 ± 7.8 | 0.079 |
| LA volume index, mL/m2 | 39.4 ± 13.3 | 40.8 ± 17.2 | 37.2 ± 13.0 | 0.245 |
| LVEDD, mm | 49.9 ± 4.7 | 49.5 ± 4.7 | 49.9 ± 4.4 | 0.804 |
| LV ejection fraction, % | 60.8 ± 9.9 | 61.6 ± 8.7 | 61.4 ± 9.7 | 0.821 |
| E/Em | 9.1 ± 3.6 | 10.5 ± 4.4 | 9.8 ± 3.9 | 0.045 |

AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category (female); TIA, transient ischemic attack; LA, left atrium; LVEDD, left ventricular end-diastolic dimension; LV, left ventricle; E/Em, early mitral inflow velocity over the early diastolic mitral annular velocity.

**Supplementary Table 2. Procedure outcomes according to the type of NOAC**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | Dabigatran(n=108) | Rivaroxaban(n=104) | Apixaban(n=114) | P-value |
| Total procedure time, min | 188.7 ± 45.3 | 201.0 ± 72.0 | 183.7 ± 57.7 | 0.105 |
| Fluoroscopic time, min | 33.9 ± 12.2 | 39.0 ± 20.0 | 32.5 ± 12.4 | 0.005 |
| Ablation time, sec | 4624.3 ± 1797.5 | 4713.8 ± 1929.8 | 4324.9 ± 1784.5 | 0.259 |
| Heparin dose, units | 19768.9 ± 7087.6 | 20862.8 ± 5198.6 | 20414.4 ± 6151.5 | 0.441 |
| Activated clotting time, sec | 347.7 ± 27.9 | 353.3 ± 33.5 | 341.9 ± 29.8 | 0.026 |
| Δ Hemoglobin, g/dL | -1.78 ± 2.21 | -1.83 ± 1.55 | -1.72 ± 1.09 | 0.889 |
| Complications, n (%) | 3 (2.8) | 5 (4.8) | 5 (4.4) | 0.725 |
| Cardiac tamponade, n (%) | 1 (0.9) | 0 | 2 (1.8) |  |
| Pericardial effusion, n (%) | 1 (0.9) | 1 (1.0) | 0 |  |
| Arteriovenous fistula, n (%) | 1 (0.9) | 1 (1.0) | 0 |  |
| Phrenic nerve damage, n (%) | 0 | 1 (1.0) | 0 |  |
| Sinus dysfunction, n (%) | 0 | 2 (1.9) | 2 (1.8) |  |
| Complete AV block, n (%) | 0 | 0 | 1 (0.9) |  |
| Stroke, n (%) | 0 | 0 | 0 |  |

AV, atrioventricular.